Britain’s GSK and France’s Sanofi on Monday mentioned they’d began a brand new scientific trial of their protein-based COVID-19 vaccine candidate and goal to succeed in the ultimate testing stage within the second quarter.

If the outcomes are conclusive, the 2 drug makers hope to see the vaccine accredited by the fourth quarter after having initially focused the primary half of this 12 months.

The transfer comes after the drug makers in December mentioned their vaccine could be delayed after scientific trials confirmed an inadequate immune response in older individuals.

The brand new trial will goal at evaluating the security, tolerability, and immune response of the vaccine in 720 wholesome adults throughout the USA, Honduras, and Panama, the businesses mentioned.

Sanofi and GSK’s candidate makes use of the identical recombinant protein-based know-how as one in all Sanofi’s seasonal influenza vaccines. It will likely be coupled with an adjuvant, a substance that acts as a booster to the shot, made by GSK.

The examine will take a look at two injections given 21 days aside.